Change in level of dyspnea when oral morphine is administered to cancer patients
Not Applicable
- Conditions
- Dyspnea in cancer patients
- Registration Number
- JPRN-UMIN000006570
- Lead Sponsor
- Central Japan Lung Study Group (CJLSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Clinical condition which can improve with other medication, such as pneumonia or heart failure is predominant. 2) Severe organ disfunction 3) History of serious allergy to morphine 4) Receiving pentazocine or buprenorphine 5) Previous registration history
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intensity of dyspnea before and after the oral morphine medication: Assessing with Visual Analog Scale (VAS)
- Secondary Outcome Measures
Name Time Method - Change of VAS in each background including causative disorder, baseline opioid, and intensity of baseline dyspnea - Cancer Dyspnea Scale - Numeric Rating Scale (NRS) - Patient's feeling of improvement - Dyspnea 48 hours after medication - Adverse events, such as respiratory depression, sleepiness, nausea, and constipation